{
  "pdfPath": "/home/arkantu/Documentos/Zotero Biblioteca/Genetica/Técnicas de laboratorio/CGH Array/Asadollahi et al_2014_The clinical significance of small copy number variants in neurodevelopmental.pdf",
  "fileName": "Asadollahi et al_2014_The clinical significance of small copy number variants in neurodevelopmental.pdf",
  "relativePath": "Genetica/Técnicas de laboratorio/CGH Array/Asadollahi et al_2014_The clinical significance of small copy number variants in neurodevelopmental.pdf",
  "text": "Genome-wide studies\n\n\n\n\n                                                                                                                                                           J Med Genet: first published as 10.1136/jmedgenet-2014-102588 on 8 August 2014. Downloaded from http://jmg.bmj.com/ on September 3, 2019 by guest. Protected by copyright.\n                                   ORIGINAL ARTICLE\n\n                                   The clinical signiﬁcance of small copy number\n                                   variants in neurodevelopmental disorders\n                                   Reza Asadollahi,1 Beatrice Oneda,1 Pascal Joset,1 Silvia Azzarello-Burri,1\n                                   Deborah Bartholdi,1 Katharina Steindl,1 Marie Vincent,1 Joana Cobilanschi,1\n                                   Heinrich Sticht,2 Rosa Baldinger,1 Regina Reissmann,1 Irene Sudholt,1\n                                   Christian T Thiel,3 Arif B Ekici,3 André Reis,3 Emilia K Bijlsma,4 Joris Andrieux,5\n                                   Anne Dieux,6 David FitzPatrick,7 Susanne Ritter,8 Alessandra Baumer,1 Beatrice Latal,8\n                                   Barbara Plecko,9 Oskar G Jenni,8 Anita Rauch1\n\n▸ Additional material is           ABSTRACT                                                       complex syndromes.2 3 Due to the extensive aetio-\npublished online only. To view     Background Despite abundant evidence for                       logical heterogeneity of NDDs, the majority of\nplease visit the journal online\n(http://dx.doi.org/10.1136/        pathogenicity of large copy number variants (CNVs) in          patients remain without aetiological diagnosis,\njmedgenet-2014-102588).            neurodevelopmental disorders (NDDs), the individual            which hampers disease management, genetic coun-\n                                   signiﬁcance of genome-wide rare CNVs <500 kb has not           selling and in-depth studies of the underlying\nFor numbered afﬁliations see\nend of article.                    been well elucidated in a clinical context.                    molecular mechanisms. With the advent of new\n                                   Methods By high-resolution chromosomal microarray              genomic technologies, however, diagnostic yield is\nCorrespondence to                  analysis, we investigated the clinical signiﬁcance of all      steadily improving and a rapidly growing number\nProfessor Anita Rauch, Institute   rare non-polymorphic exonic CNVs sizing 1–500 kb in a          of novel, aetiologically deﬁned disorders are\nof Medical Genetics, University\nof Zurich, Wagistrasse 12,         cohort of 714 patients with undiagnosed NDDs.                  delineated.\nSchlieren-Zurich CH-8952,          Results We detected 96 rare CNVs <500 kb affecting                Genome-wide chromosomal microarray analysis\nSwitzerland;                       coding regions, of which 58 (60.4%) were conﬁrmed.             (CMA) for detection of copy number variants\nanita.rauch@medgen.uzh.ch          6 of 14 conﬁrmed de novo, one of two homozygous and            (CNVs) is currently used as a ﬁrst-tier diagnostic\nReceived 18 June 2014\n                                   four heterozygous inherited CNVs affected the known            approach in patients with idiopathic NDDs. The\nRevised 18 July 2014               microdeletion regions 17q21.31, 16p11.2 and 2p21 or            diagnostic yield of clinically signiﬁcant CNVs varies\nAccepted 21 July 2014              OMIM morbid genes (CASK, CREBBP, PAFAH1B1,                     between 5% and 20%, depending on the clinical\nPublished Online First             SATB2; AUTS2, NRXN3, GRM8). Two further de novo                preselection and resolution of the array.4 Despite\n8 August 2014                      CNVs affecting single genes (MED13L, CTNND2) were              their obvious higher sensitivity, the widespread use\n                                   instrumental in delineating novel recurrent conditions.        of high-resolution arrays, however, is hampered by\n                                   For the ﬁrst time, we here report exonic deletions of          their inherent burden of detecting polymorphic or\n                                   CTNND2 causing low normal IQ with learning difﬁculties         unclear variants. Indeed, tiling array studies have\n                                   with or without autism spectrum disorder. Additionally,        revealed a huge diversity of CNVs in the general\n                                   we discovered a homozygous out-of-frame deletion of            population with an overall median length of about\n                                   ACOT7 associated with features comparable to the               2.9 kb and 95% being less than 100 kb.5\n                                   published mouse model. In total, 24.1% of the                  Furthermore, CNVs larger than 500 kb were\n                                   conﬁrmed small CNVs were categorised as pathogenic or          shown to occur only in about 10% of control indi-\n                                   likely pathogenic (median size 130 kb), 17.2% as likely        viduals, while patients with NDDs harbour an add-\n                                   benign, 3.4% represented incidental ﬁndings and 55.2%          itional burden of more than 13.5% for such\n                                   remained unclear.                                              CNVs.6 Accordingly, a 2010 consensus statement\n                                   Conclusions These results verify the diagnostic                on diagnostic chromosomal microarray testing\n                                   relevance of genome-wide rare CNVs <500 kb, which              recommends a resolution of ≥400 kb throughout\n                                   were found pathogenic in ∼2% (14/714) of cases (1.1%           the genome as a balance of analytical and clinical\n          Open Access              de novo, 0.3% homozygous, 0.6% inherited) and                  sensitivity.4 Therefore, the individual signiﬁcance of\n       Scan to access more         highlight their inherent potential for discovery of new        rare small CNVs has not been well elucidated in a\n          free content\n                                   conditions.                                                    clinical context, but is of rising interest given the\n                                                                                                  recent progress in detection of small CNVs from\n                                                                                                  whole-exome sequencing (WES) data.7–9\n                                                                                                     Therefore, in this study, we investigated the diag-\n                                   INTRODUCTION                                                   nostic relevance and inherent potential for gene\n                                   Neurodevelopmental disorders (NDDs) are a group                discovery of rare CNVs sizing 1–500 kb in a cohort\n                                   of conditions characterised by cognitive, neuro-               of 714 patients with isolated or syndromic NDDs.\n                                   logical and/or psychiatric manifestations occurring\n                                   during the development of the nervous system.1\n                                   The various clinical entities such as intellectual dis-        METHODS\n To cite: Asadollahi R,            ability (ID), speech and language delay, autism,               Excluding patients with large-scale chromosomal\n Oneda B, Joset P, et al.          neuromotor dysfunction or epilepsy show consider-              aberrations, CNVs >10 Mb, or clinically recog-\n J Med Genet 2014;51:              able comorbidity and may be associated with a                  nised recurrent microdeletion syndromes, we inves-\n 677–688.                          variety of non-neurological features within                    tigated 714 patients with NDDs with or without\n\n                                          Asadollahi R, et al. J Med Genet 2014;51:677–688. doi:10.1136/jmedgenet-2014-102588                       677\n\f Genome-wide studies\n\n\n\n\n                                                                                                                                                        J Med Genet: first published as 10.1136/jmedgenet-2014-102588 on 8 August 2014. Downloaded from http://jmg.bmj.com/ on September 3, 2019 by guest. Protected by copyright.\nfurther congenital anomalies by genome-wide high-resolution             Exome sequencing and mutation analysis\nCMA. The vast majority of patients were of European origin.             WES on genomic DNA of selected patients was performed as\nAmong them, 63 patients (8.8%) had obvious pathogenic CNVs              described before with minor modiﬁcations.13 14 All exons and\n>500 kb with a median size of 3.8 Mb.                                   ﬂanking intronic nucleotides of candidate genes from CMA or\n   We investigated CNVs sizing 1–500 kb for their overlap with          candidate nucleotide variants from WES were analysed after\nannotated exons as well as with in-house and public control data-       PCR ampliﬁcation from patient’s DNA by Sanger sequencing\nbases. CNVs affecting exonic regions that were not observed in          using an ABI Genetic Analyzer 3730 (Applied Biosystems,\nour in-house controls or only reported once in public databases         Foster City, California, USA).\nwere tested by multiplex ligation-dependent probe ampliﬁcation\n(MLPA) or ﬂuorescence in situ hybridization (FISH) if not already       Expression studies of ACOT7\nconﬁrmed by inheritance pattern from trio microarray analysis.          Expression levels were investigated in cDNA panels from fetal\nConﬁrmed CNVs were individually assessed regarding literature           and adult human tissues using customised SYBR green qPCR for\nevidence for pathogenicity, overlapping CNVs in the DECIPHER            exons 1 and 2 of ACOT7 (speciﬁc for isoform\ndatabase,10 function and expression proﬁles of the affected gene(s)     ENST00000377855). Relative expression levels normalised to\nand inheritance pattern. Selected candidate genes within inherited      Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were set\nrare CNVs were further studied by Sanger sequencing for biallelic       into relation to the mean expression value of this isoform in\nmutations. Five patients were further investigated for non-allelic      fetal brain.\nhits by WES. Four of these patients were selected for WES because\nthey had de novo CNVs affecting good candidate genes but\n                                                                        Statistical analysis\nlacking overlapping cases at the time of analysis, and one patient\n                                                                        Statistical differences for size, number of markers/size and conﬁ-\nwas exome sequenced because an inherited variant was present in\n                                                                        dence value of CNVs were analysed using Mann-Whitney\nthree affected siblings.\n                                                                        U-testing and independent-samples t testing. p Values less than\n                                                                        0.05 were considered statistically signiﬁcant.\n\nMicroarray and conﬁrmatory studies                                      RESULTS\nDNA, extracted from peripheral blood, was analysed with                 Among the 714 array results, 96 aberrations below 500 kb fulﬁlled\nAffymetrix Genome-Wide Human SNP Array 6.0 (1.8 million                 the abovementioned criteria and were further evaluated (size range\nmarkers; 79 patients), Affymetrix Cytogenetics 2.7 (2.7 million         2–492 kb, median 72 kb). In total, 58 out of 96 (60.4%) of these\nmarkers; 423 patients) and CytoScan HD (2.6 million markers;            selected CNVs were conﬁrmed by secondary testing, while 38 of\n212 patients) (Affymetrix Inc., Santa Clara, California, USA).          96 (39.6%) were not conﬁrmed and thus considered false positive\nThe average intermarker spacing was 1.6 kb for the 6.0 array            (see online supplementary table S1). False positive aberrations\nand about 1.1 kb for the two other arrays. CNVs were called if          were signiﬁcantly smaller in size (3–181 kb, median 19 kb, mean\nthey encompassed at least ﬁve consecutive markers resulting in a        45.3 kb) than true CNVs (2–492 kb, median 131 kb, mean\nmaximum resolution of about 2 kb. The data set of each                  164.7 kb) (p<0.0001; ﬁgure 1A). There was also a signiﬁcant dif-\npatient’s sample was evaluated with Affymetrix Chromosome               ference between the two groups regarding their conﬁdence values\nAnalysis Suite (ChAS V.1.0.1) in comparison with 670 controls           (mean of 88.9% vs 91.9%, p<0.0001; ﬁgure 1B) and marker\nin the 6.0 array, 820 controls in the 2.7 array and 1038 controls       count (median of 20 (8–142) vs 96 (6–1040), mean of 39.9 vs\nin the CytoScan array. Controls consisted of European and               163.8, p<0.0001; ﬁgure 1C), while no signiﬁcant difference was\nAmerican healthy individuals. Categorisation of CNVs by the             observed for the marker count per kb within the CNV (1.5±1.14\nAffymetrix’s ChAS software among others includes conﬁdence              vs 1.1±0.67, p=0.1; ﬁgure 1D). Since the 1:2 copy number\nvalues for the 2.7 and CytoScan arrays. Conﬁdence is deter-             reduction in deletions is more easily detectable than the 3:2 copy\nmined on a marker by marker basis by evaluating the concord-            number gain in duplications, sensitivity and speciﬁcity is different\nance of the log2ratio at each marker with the copy number state         for deletions and duplications. Duplications sizing at least 183 kb\nassigned by the hidden Markov model (HMM). The average                  or encompassing at least 168 markers were all true positives, while\nconﬁdence score of markers in gain and loss segments deter-             deletions were reliable if they sized at least 113 kb or encompassed\nmines the conﬁdence score of that segment.                              at least 52 markers.\n   Readily available kits or customised MLPA was performed                 Among 58 conﬁrmed CNVs, 14 (24.1%) were de novo (table 1),\nusing synthetic probes for selected exons and the SALSA MLPA            2 (3.4%) were homozygous and 39 (67.2%) were heterozygous\nkit P300 Human DNA reference-2 (MRC-Holland, Amsterdam,                 and inherited (19 from mothers and 20 from fathers). While for 12\nThe Netherlands). The MLPA module of the Sequence Pilot                 of 14 de novo CNVs both parents were available for testing, in\n3.5.2 Build 508 software ( JSI medical systems GmbH,                    another two CNVs de novo origin was assumed based on their\nKippenheim, Germany) was used to retrieve relative peak inten-          well-established causal involvement in severe and fully penetrant\nsities by normalisation to the reference probe set. Normalised          phenotypes (one exonic deletion within the PAFAH1B1 gene\npeak levels were set in relation to at least three healthy control      causing lissencephaly type 1 and the recurrent 473 kb microdele-\nindividuals. FISH analyses were performed using locus-speciﬁc           tion in 17q21.31) (table 1). For two further CNVs (3.4%), patterns\ncommercial probes according to standard protocols on meta-              of inheritance could not be completely tested because the fathers\nphase preparations from peripheral blood.                               were not available, but due to familial recurrence they were consid-\n                                                                        ered likely inherited (see online supplementary table S2). One inci-\n                                                                        dental ﬁnding (DMD deletion) was not tested in the mother.\nSATB2 protein modelling\nThe protein was modelled with Modeller 9.9,11 based on the              De novo CNVs\ncrystal structure of the homologous SATB1 tetramer 12 that              Six de novo or likely de novo CNVs were clearly pathogenic\nexhibits 78% sequence identity.                                         affecting the recurrent microdeletion region in 17q21.31\n\n678                                                               Asadollahi R, et al. J Med Genet 2014;51:677–688. doi:10.1136/jmedgenet-2014-102588\n\f                                                                                                                    Genome-wide studies\n\n\n\n\n                                                                                                                                                      J Med Genet: first published as 10.1136/jmedgenet-2014-102588 on 8 August 2014. Downloaded from http://jmg.bmj.com/ on September 3, 2019 by guest. Protected by copyright.\nFigure 1 Comparison between true versus false positive status of small copy number variants (CNVs) detected by chromosomal microarray analysis\n(CMA) and their size, conﬁdence value, marker count and marker count per kb. (A) False positive CNVs were signiﬁcantly smaller in size (3–181 kb,\nmedian 19 kb, mean 45.3 kb) than true CNVs (2–492 kb, median 131 kb, mean 164.7 kb) ( p<0.0001). (B) There was also a signiﬁcant difference\nbetween the two groups regarding their conﬁdence values (mean of 88.9% vs 91.9%, p<0.0001) and (C) marker count (median of 20 vs 96, mean\nof 39.9 vs 163.8, p<0.0001). (D) No signiﬁcant difference was observed for the marker count per kb within the CNV (1.5±1.14 vs 1.1±0.67, p=0.1).\n\n(detected in two cases), well-characterised OMIM morbid genes                     However, extended deletion mapping indicated that interstitial\n(CASK, CREBBP, PAFAH1B1) or the recently described SATB2                          deletions restricted to the ID critical region 2 (MRII) including\nlocus (table 1). For two further de novo CNVs affecting single                    the CTNND2 locus produce a milder level of intellectual\ngenes (MED13L, CTNND2), similar cases were identiﬁed in the                       impairment.18 CNVs encompassing CTNND2 have been impli-\nDECIPHER database (http://decipher.sanger.ac.uk/). The 17 kb                      cated in autism (one deletion, de novo),19 cerebral palsy (one\nout-of-frame de novo deletion encompassing exon 2 of                              duplication including the ﬁrst exon of CTNND2, maternally\nMED13L (MIM *608771) in patient 56366, together with over-                        inherited)20 and schizophrenia (one duplication affecting seven\nlapping cases, were instrumental to deﬁne a recognisable hap-                     genes including CTNND2).21\nloinsufﬁciency syndrome that we reported and discussed in                            CMA in our patient revealed a 113 kb de novo out-of-frame\ndetail elsewhere.13 The novel condition caused by CTNND2                          deletion encompassing exons 4–7 of CTNND2. Sanger sequen-\nhaploinsufﬁciency is described for the ﬁrst time below. We also                   cing in the patient did not reveal an additional pathogenic\nreport a special tooth phenotype found in our patient with                        point mutation of the gene. The girl was born spontaneously\nSATB2 defect. Additionally, we discuss a de novo variant limited                  at term with normal measurements and no complication to\nto the DNM3 gene, which is the candidate critical gene in                         highly educated unrelated parents. She had no remarkable\n1q24-q25 deletions, as well as two de novo CNVs classiﬁed as                      health issues and developmental milestones and growth para-\nlikely benign after identiﬁcation of pathogenic mutations by                      meters were within normal limits (table 2). Physical examin-\nWES.                                                                              ation revealed deep set eyes, prominent cheeks, narrow\n                                                                                  eyebrows, short inner canthal distance (ICD 2.7 cm, 2nd\nNovel CTNND2-related phenotype deﬁned by patient 62563 with                       centile), low-set, slightly backwards rotated ears, and a bulbous\n113 kb deletion and overlapping cases                                             nose with prominent columella. She had mild clinodactyly of\nCTNND2 (MIM *604275) encodes δ-catenin, which functions                           the ﬁfth ﬁnger, which was also present in the healthy brother.\nas a regulator of neuronal migration15 and maintenance of den-                    She was referred to formal developmental testing at age 8 years\ndrites and dendritic spines in mature cortex.16 It was mapped to                  because of behavioural issues and was diagnosed with border-\nthe cri-du-chat syndrome critical region in chromosome 5p15.2                     line ID (WISC-IV, full scale IQ 77). She showed a dissociated\nand was considered responsible for severe ID in typical                           cognitive proﬁle with better language (vocabulary, comprehen-\ncri-du-chat syndrome patients with terminal 5p deletions.17                       sion, reading) than non-verbal functions (visual perception,\n\nAsadollahi R, et al. J Med Genet 2014;51:677–688. doi:10.1136/jmedgenet-2014-102588                                                            679\n\f680\n\n\n\n\n                                                                                                                                                                                                                                                                                                      Genome-wide studies\n                                                                                      Table 1   Clinical and genetic features of patients with candidate de novo CNVs <500 kb sorted by descending size\n                                                                                      Patient   Age*                                                                 Chromosome                          Size   Confidence   Marker   Affected\n                                                                                      ID        (years)   Gender   Phenotype                        Aberration       band         Genome coordinates     (kb)   value (%)    count    gene(s)       Validation       Pathogenicity\n\n                                                                                      52253      5        M        Developmental delay, marked      Deletion         17q21.31      hg18, chr17:          473    N/A          329      9 genes       MLPA/-(parents   Pathogenic (recurrent\n                                                                                                                   hypotonia, agenesis of corpus    (heterozygous)                41049320-41522088                                   including     N/A, likely de   microdeletion syndrome)58\n                                                                                                                   callosum and facial                                                                                                MAPT          novo)\n                                                                                                                   dysmorphic features\n                                                                                      69234      2        F        Developmental delay,             Deletion         Xp11.4       hg19, chrX:            472    91           1040     CASK,         MLPA/de novo     Pathogenic (phenotypic\n                                                                                                                   hypotonia, microcephaly and      (heterozygous)                41339667-41811516                                   GPR34 and                      spectrum associated with\n                                                                                                                   minor morphological                                                                                                GPR82                          CASK loss of function has\n                                                                                                                   abnormalities                                                                                                                                     been described)59\n                                                                                      71264      2        M        Developmental delay,             Deletion         17q21.31     hg19, chr17:           459    90           857      9 genes       MLPA/de novo     Pathogenic (recurrent\n                                                                                                                   hypotonia, mild facial           (heterozygous)                43703800-44163085                                   including                      microdeletion syndrome)58\n                                                                                                                   dysmorphic features and                                                                                            MAPT\n                                                                                                                   stridor\n                                                                                      59248      4        F        Developmental delay, severe      Deletion         1q24.3       hg18, chr1:            372    N/A          244      DNM3          FISH/de novo     VOUS (WES of the patient and\n                                                                                                                   hypotonia since birth,           (heterozygous)                170135864-170505998                                                                both parents did not reveal\n                                                                                                                   refractory epilepsy, facial                                                                                                                       any obvious candidate gene\n                                                                                                                   dysmorphic features and                                                                                                                           mutation. DNM3 encodes\n                                                                                                                   oedematous hands and feet                                                                                                                         dynamin 3, involved in\n                                                                                                                   with tapering fingers                                                                                                                             vesicular transport)\n                                                                                      71156      1        F        Developmental delay,             Deletion         16p13.3      hg19, chr16:           147    91           353      CREBBP        MLPA/de novo     Pathogenic (OMIM gene for\n                                                                                                                   microcephaly and facial          (heterozygous)                3788867- 3935836                                                                   Rubinstein–Taybi syndrome)48\n                                                                                                                   dysmorphic features\nAsadollahi R, et al. J Med Genet 2014;51:677–688. doi:10.1136/jmedgenet-2014-102588\n\n\n\n\n                                                                                      62848      5        F        Developmental delay,             Duplication      12q24.23     hg18, chr12:           122    N/A            71     TAOK3 and     MLPA/de novo     Likely benign (pathogenic\n                                                                                                                   hyperactivity and microcephaly   (heterozygous)                117061815- 117183853                                PEBP1                          heterozygous mutation in\n                                                                                                                                                                                                                                                                     SHANK2: c.2669_2670insC (p.\n                                                                                                                                                                                                                                                                     P891Sfs*32) was found in this\n                                                                                                                                                                                                                                                                     patient by WES)\n                                                                                      62563     11        F        Learning difficulties, short     Deletion         5p15.2       hg18, chr5:            113    N/A            99     CTNND2        MLPA/de novo     Pathogenic (implicated in the\n                                                                                                                   attention, deficits in           (heterozygous)                11431816- 11545236                                                                 ID phenotype of cri-du-chat\n                                                                                                                   social-emotional behaviour                                                                                                                        syndrome.17 Further patients\n                                                                                                                   and mild facial dysmorphic                                                                                                                        are discussed in this paper)\n                                                                                                                   features\n                                                                                      72125      7        F        Developmental delay, and mild    Duplication      10p14        hg19, chr10:           101    90           108      TAF3          MLPA/de novo     VOUS (TAF3 encodes TAF3\n                                                                                                                   facial dysmorphic features       (heterozygous)                7932363-8033508                                                                    RNA polymerase II, TATA box\n                                                                                                                                                                                                                                                                     binding protein-associated\n                                                                                                                                                                                                                                                                     factor)\n                                                                                      70229      3        M        Global developmental delay       Deletion         12q24.33     hg19, chr12:            71    90             48     EP400,        MLPA/de novo     VOUS (there is patient 262376\n                                                                                                                   with prominent speech delay,     (heterozygous)                132552537-132623611                                 EP400NL,                       in Decipher database with a\n                                                                                                                   truncal ataxia, agenesis of                                                                                        and DDX51                      duplication encompassing the\n                                                                                                                   corpus callosum and repaired                                                                                                                      same genes)\n                                                                                                                   cleft palate\n                                                                                      43552     19        M        Intellectual disability (ID),    Deletion         16p13.3      hg18, chr16:            60    89             53     NAGPA,        MLPA/de novo     VOUS (a smaller deletion\n                                                                                                                   speech problems, spastic         (heterozygous)                4986264- 5046682                                    C16orf89,                      including only SEC14L5 and\n                                                                                                                   movement disorder and tall                                                                                         and SEC14L5                    NAGPA is present in 1/1038 of\n                                                                                                                   stature                                                                                                                                           a world-wide control cohort by\n                                                                                                                                                                                                                                                                     Affymetrix)\n                                                                                      70886      4        M                                                          2q33.1                               32    89             68     SATB2         MLPA/de novo\n                                                                                                                                                                                                                                                                                         Continued\n\n\n\n                                                                                      J Med Genet: first published as 10.1136/jmedgenet-2014-102588 on 8 August 2014. Downloaded from http://jmg.bmj.com/ on September 3, 2019 by guest. Protected by copyright.\n\f                                                                                                                                                                                                                                                                                                  Genome-wide studies\n\n\n\n\n                                                                                                                                                                                                                                                                                                                                       J Med Genet: first published as 10.1136/jmedgenet-2014-102588 on 8 August 2014. Downloaded from http://jmg.bmj.com/ on September 3, 2019 by guest. Protected by copyright.\n                                                                                                                                                                                                                                                               abstract reasoning). She also showed short attention span, poor\n\n\n                                       Pathogenic (deletions of SATB2\n\n\n\n\n                                       mosaic heterozygous mutation\n                                                                                                                                                                                                                                                               executive functioning and impaired working memory. The cog-\n\n\n\n                                       causative for cleft palate and\n\n\n\n\n                                                                                                             Pathogenic (OMIM gene for\n                                       in PIK3CA: c.2740G>A (p.\n                                                                                                                                                                                                                                                               nitive proﬁle remained stable at follow-up. Although immature\n\n\n\n\n                                       Likely benign (pathogenic\n\n\n                                       G914R) was found in this\n                                       have been implicated as\n                                                                                                                                                                                                                                                               social-emotional behaviour was described, formal signs of\n\n\n\n\n                                       Pathogenic (described\n                                                                                                                                                                                                                                                               autism were not present.\n\n\n\n\n                                       patient by WES)34\n\n\n\n\n                                                                                                             lissencephaly)60\n                  Pathogenicity\n\n\n\n\n                                                                                                                                                                                                                                                                  We found three further patients with exonic deletions limited\n\n\n\n\n                                       elsewhere)13\n                                                                                                                                                                                                                                                               to CTNND2 via the DECIPHER database (table 2, ﬁgure 2).\n                                                                                                                                                                                                                                                               These three deletions were inherited and for two transmitting\n                                       ID)26\n\n\n\n                                                                                                                                                                                                                                                               parents low normal IQ was recognised. Because exonic\n                                                                                                                                                                                                                                                               CTNND2 deletions are not reported in the normal population\n                                                                                                                                                                                                                                                               databases and since these patients as well as two of the three\n\n\n\n\n                                                                                                             MLPA/-(parents\n                                                                       MLPA/de novo\n\n\n\n\n                                                                                            MLPA/de novo\n\n\n\n\n                                                                                                             N/A, likely de\n                                                                                                                                                                                                                                                               transmitting parents share borderline low IQ or mild ID with or\n                  Validation\n\n\n\n\n                                                                                                                                                                                                                                                               without autistic behavioural problems, we assume that\n\n\n\n\n                                                                                                             novo)\n                                                                                                                                                                                                                                                               CTNND2 haploinsufﬁciency is causing the neurodevelopmental\n                                                                                                                                                                                                                                                               features in these patients. Given the mild phenotype of the\n                                                                                                                                                                                                                                                               patients, transmission by seemingly normal parents may be\n                                                                                                             PAFAH1B1\n                                                                                                                                                                                                                                                               explained by clinical variability or lack of formal cognitive\n                                                                       TH1L and\n             Affected\n\n\n\n\n                                                                                            MED13L\n             gene(s)\n\n\n\n\n                                                                                                             (LIS1)                                                                                                                                            testing. The progressive neurological signs in patient 4\n                                                                       CTSZ\n\n\n\n\n                                                                                                                                                                                                                                                               (DECIPHER 271234), however, may be caused by an additional\n                                                                                                                                                                                                                                                               unidentiﬁed disorder.\n             Marker\n             count\n\n\n\n\n                                                                       28\n\n\n\n\n                                                                                            18\n\n\n\n\n                                                                                                             6\n\n\n\n\n                                                                                                                                                                                                                                                               SATB2 intragenic 32 kb duplication in patient 70886 with ID and\n                                                                                                                                                                                                                                                               double row of upper incisors\n                                                                                                                                                                                                                                                               SATB2 (special AT-rich sequence binding protein 2; MIM\n             Confidence\n             value (%)\n\n\n\n\n                                                                                                                                                                                                                                                               *608148) is a DNA-binding protein that regulates gene expres-\n                                                                                                                                                                                                                                                               sion and corticocortical connections in the developing cerebral\n                                                                       94\n\n\n\n\n                                                                                            87\n\n\n\n\n                                                                                                             96\n\n\n\n\n                                                                                                                                                                                                                                                               cortex and craniofacial patterning.22 23 De novo interrupting\n                                                                                                                                                                                                                                                               translocations, microdeletions and mutations of SATB2 have\n             Size\n             (kb)\n\n\n\n\n                                                                       19\n\n\n\n\n                                                                                            17\n\n\n\n\n                                                                                                             4\n\n\n\n\n                                                                                                                                                                                                                                                               been described in patients with ID, behavioural problems, sei-\n                                                                                                                                                                                                                                                               zures and craniofacial anomalies with or without cleft\n                                       200278502- 200310272\n                  Genome coordinates\n\n\n\n\n                                                                                                                                                                                                                                                               palate.14 24–28 The duplication detected by CMA in our patient\n                                                                       57556968- 57575495\n\n\n\n\n                                                                                                             2519114- 2523280\n\n\n\n\n                                                                                                                                                                                                                                                               affects exon 4 (c.170-?_346+?; p.Gly57_Gln115dup)\n                                                                                                                                                                                                                                                               (ENST00000457245) and is predicted by homology modelling\n                                                                       hg19, chr20:\n\n\n\n\n                                                                           ",
  "wordCount": 10660,
  "indexed": "2025-09-25T22:44:02.646Z",
  "method": "direct"
}
